Definigen
1 known investors
Definigen (Pixl Bio Ltd.) combines human iPSC-derived cell models—including hepatocytes, stellates, organoids, and CRISPR-edited disease models—with AI-driven phenomics and high-content imaging to generate predictive biological data for drug discovery and safety assessment. It serves biopharmaceutical companies through products and custom research services covering functional assays, phenomic analysis, and toxicology or mechanism-of-action studies.
AI & Machine LearningBiotechHealthtech
Investors · 1
Frequently asked questions
- What does Definigen do?
- Definigen (Pixl Bio Ltd.) combines human iPSC-derived cell models—including hepatocytes, stellates, organoids, and CRISPR-edited disease models—with AI-driven phenomics and high-content imaging to generate predictive biological data for drug discovery and safety assessment. It serves biopharmaceutical companies through products and custom research services covering functional assays, phenomic analysis, and toxicology or mechanism-of-action studies.
- Who are Definigen's investors?
- Definigen's investors include 24 Haymarket.